ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

Ulutas Med J. 2019; 5(3): 225-228


A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?

Habibullah Aktas, Serkan Oner, Zulal Oner.



Abstract
Download PDF Cited by 0 ArticlesPost

Background: Scleredema diabeticorum is a dermatosis characterized by hardening of skin over the upper back. It is commonly seen in poor-controlled diabetic patients. Therapeutic options are limited. Psoralen and ultraviolet A therapy (PUVA), methotrexate, and topical steroids have been used with some success. Pentoxifylline is a xanthine derivative used mainly in peripheral vascular diseases. It also has antifibrotic effects due to its collagen synthesis inhibition action.
Case Presentation: In this paper, a trial of intralesional pentoxifylline treatment and magnetic resonance images of a male patient with scleredema diabeticorum are presented. Some subjective symptoms of the patient improved after this treatment, but, the thickness of the lesion did not change.
Conclusion: Pentoxifylline, probably via the oral route, could still be thought in such patients unresponsive to conventional approaches due to its antifibrotic activity and high safety profile.

Key words: Scleredema, Pentoxifylline, MRI







Bibliomed Article Statistics

40
61
55
29
25
17
21
18
23
26
23
10
R
E
A
D
S

42

54

106

61

46

20

12

49

33

45

47

13
D
O
W
N
L
O
A
D
S
040506070809101112010203
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.